Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS‐CoV‐2 - Institut Pierre Louis d'Epidémiologie et de Santé Publique
Article Dans Une Revue Influenza and Other Respiratory Viruses Année : 2024

Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS‐CoV‐2

Quentin Richier

Résumé

The emergence of SARS-CoV-2 Omicron variant has led to a complete reconfiguration of the therapeutic landscape, with all monoclonal antibodies having lost any neutralization activity. We report here a case series of 75 immunocompromised patients infected by the Omicron variant who benefited from COVID-19 convalescent plasma (CCP). At Day 28, the overall survival was 76% (95% CI 67-86) with no significant difference in the clinical outcome between patients with hematological malignancies, solid organ transplantation or autoimmune diseases. No safety concern was reported during the course of the study. These results showed that CCP is well tolerated and represents a treatment option for immunocompromised patients who remain highly impacted by the COVID19 epidemic.
Fichier principal
Vignette du fichier
Richier_2024.pdf (571.29 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
licence

Dates et versions

hal-04710052 , version 1 (26-09-2024)

Licence

Identifiants

Citer

Quentin Richier, Benjamin de Valence, Dorothée Chopin, Emmanuelle Gras, Laura I Levi, et al.. Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS‐CoV‐2. Influenza and Other Respiratory Viruses, 2024, 18 (3), pp.e13272. ⟨10.1111/irv.13272⟩. ⟨hal-04710052⟩
37 Consultations
5 Téléchargements

Altmetric

Partager

More